[go: up one dir, main page]

PT2668182T - Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune - Google Patents

Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune

Info

Publication number
PT2668182T
PT2668182T PT127030138T PT12703013T PT2668182T PT 2668182 T PT2668182 T PT 2668182T PT 127030138 T PT127030138 T PT 127030138T PT 12703013 T PT12703013 T PT 12703013T PT 2668182 T PT2668182 T PT 2668182T
Authority
PT
Portugal
Prior art keywords
ifn
treatment
autoimmune inflammation
gamma inhibition
gamma
Prior art date
Application number
PT127030138T
Other languages
English (en)
Inventor
Leban Johann
Baumgartner Roland
Saeb Wael
Chevrier Carine
Tasler Stefan
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of PT2668182T publication Critical patent/PT2668182T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT127030138T 2011-01-28 2012-01-27 Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune PT2668182T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437061P 2011-01-28 2011-01-28
EP11152515 2011-01-28

Publications (1)

Publication Number Publication Date
PT2668182T true PT2668182T (pt) 2018-01-31

Family

ID=46577835

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127030138T PT2668182T (pt) 2011-01-28 2012-01-27 Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune

Country Status (24)

Country Link
US (1) US8592456B2 (pt)
EP (1) EP2668182B1 (pt)
JP (1) JP5969505B2 (pt)
KR (1) KR101875248B1 (pt)
CN (1) CN103476771B (pt)
AR (1) AR085040A1 (pt)
AU (1) AU2012210489B2 (pt)
BR (1) BR112013019011B1 (pt)
CA (1) CA2825684C (pt)
DK (1) DK2668182T3 (pt)
EA (1) EA027351B1 (pt)
ES (1) ES2664507T3 (pt)
IL (1) IL227626A0 (pt)
MX (1) MX353762B (pt)
MY (1) MY162397A (pt)
PH (1) PH12013501574A1 (pt)
PL (1) PL2668182T3 (pt)
PT (1) PT2668182T (pt)
RU (1) RU2013139663A (pt)
SG (1) SG192176A1 (pt)
TW (1) TWI520955B (pt)
UA (1) UA113160C2 (pt)
UY (1) UY33884A (pt)
WO (1) WO2012101261A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2668183T3 (pl) * 2011-01-28 2018-10-31 Immunic Ag Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
CN107007597A (zh) 2012-05-31 2017-08-04 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN104978732A (zh) * 2014-04-11 2015-10-14 中国船舶工业系统工程研究院 一种摄像机参数标定板
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека
CN111433202A (zh) * 2017-09-06 2020-07-17 埃慕尼克股份公司 作为IL-17和IFN-γ抑制剂用于治疗自体免疫疾病和慢性炎症的1-(4-(异*唑-5-基)-1H-吡唑-1-基)-2-甲基丙-2-醇衍生物和相关化合物
WO2019223718A1 (zh) * 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341435B (zh) * 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341440B (zh) * 2019-08-09 2022-05-31 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341519B (zh) * 2019-08-09 2025-10-03 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) * 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
US20240368145A1 (en) 2021-07-09 2024-11-07 Immunic Ag Methods for treating cancer
US20250243190A1 (en) 2022-04-14 2025-07-31 Immunic Ag New deuterated rorgamma/rorgammat inverse agonists
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172985T1 (de) * 1993-02-09 1998-11-15 Bayer Ag Sulfonamidaminomethylenderivate als immunsuppressiva
JP3237608B2 (ja) * 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
ES2248894T3 (es) * 1997-04-21 2006-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivados de isoxazol.
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
ATE432273T1 (de) * 2004-03-09 2009-06-15 Boehringer Ingelheim Pharma 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n- arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2009300317A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AR076984A1 (es) * 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
PL2668183T3 (pl) * 2011-01-28 2018-10-31 Immunic Ag Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego

Also Published As

Publication number Publication date
PL2668182T3 (pl) 2018-11-30
UA113160C2 (xx) 2016-12-26
US20120196861A1 (en) 2012-08-02
EP2668182B1 (en) 2017-11-01
IL227626A0 (en) 2013-09-30
EA027351B1 (ru) 2017-07-31
NZ613592A (en) 2015-03-27
TW201309682A (zh) 2013-03-01
CN103476771A (zh) 2013-12-25
AU2012210489B2 (en) 2017-01-12
KR101875248B1 (ko) 2018-08-02
EP2668182A1 (en) 2013-12-04
UY33884A (es) 2012-08-31
EA201300862A1 (ru) 2014-04-30
SG192176A1 (en) 2013-08-30
MX2013008718A (es) 2014-02-17
BR112013019011B1 (pt) 2021-10-13
TWI520955B (zh) 2016-02-11
CA2825684C (en) 2021-11-23
JP2014504608A (ja) 2014-02-24
CN103476771B (zh) 2015-12-23
CA2825684A1 (en) 2012-08-02
JP5969505B2 (ja) 2016-08-17
MY162397A (en) 2017-06-15
BR112013019011A2 (pt) 2017-07-11
PH12013501574A1 (en) 2013-09-30
WO2012101261A1 (en) 2012-08-02
MX353762B (es) 2018-01-26
DK2668182T3 (da) 2018-01-29
RU2013139663A (ru) 2015-03-10
AR085040A1 (es) 2013-08-07
US8592456B2 (en) 2013-11-26
AU2012210489A1 (en) 2013-08-15
ES2664507T3 (es) 2018-04-19
KR20140041440A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
PT2668182T (pt) Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune
PT2668183T (pt) Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune
IL273815B (en) Secondary vaccine particles for the treatment of inflammation
IL261768B (en) Devices and methods for tissue treatment
TWI560200B (en) Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
EP2709562A4 (en) FABRIC BACKUP DEVICES AND USE METHOD THEREFOR
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2699199A4 (en) SYSTEMS AND METHODS FOR BARIATRIC THERAPY
SG10201707020TA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
IL233111A0 (en) Preparations for the treatment of inflammation
GB201411462D0 (en) Prebiotic formulations and methods of use
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
IL229079A0 (en) Methods and compositions using 4pde inhibitors for the treatment and management of autoimmune and inflammatory diseases
PH12014500815A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
EP2866830A4 (en) ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR THE INHIBITION OF INFLAMMATION
ZA201408055B (en) Compositions and methods for the treatment of local pain
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
IL233080B (en) Bisarylsulfonamides used to treat inflammation and cancer
IL239308A0 (en) Treatment of diseases of endothelial dysfunction and inflammation
IL223385B (en) Treatment of inflammatory disorders
PL2744497T3 (pl) Terapeutyczne połączenia netupitantu i palonosetronu
ZA201306087B (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
ZA201408045B (en) Compositions and methods for the treatment of inflammation and lipid disorders